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Key Messages
1. A SARS vaccine was produced based 
on recombinant native full-length 
Spike-protein trimers (triSpike) and 
efficient establishment of a vaccination 
procedure in rodents.
2. Antibody-mediated enhancement 
of SARS-CoV infection with anti-
SARS-CoV Spike immune-serum was 
observed in vitro.
3. Antibody-mediated infection of 
SARS-CoV triggers entry into human 
haematopoietic cells via an FcγR-
dependent and ACE2-, pH-, cysteine-
protease-independent pathways.
4. The antibody-mediated enhancement 
phenomenon is not a mandatory 
component of the humoral immune 
response elicited by SARS vaccines, as 
pure neutralising antibody only could 
be obtained.
5. Occurrence of immune-mediated 
enhancement of SARS-CoV infection 
raises safety concerns regarding the use 
of SARS-CoV vaccine in humans and 
enables new ways to investigate SARS 
pathogenesis (tropism and immune 
response deregulation).
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Introduction
Public health measures successfully contained outbreaks of the severe acute 
respiratory syndrome coronavirus (SARS-CoV), which infected more than 8000 
people worldwide with a mortality of about 10%. However, concerns over future 
recurrences remain. Continuous efforts have been made to develop safe vaccine 
strategies against SARS-CoV.
 Among the four major structural SARS-CoV proteins, the Spike envelope 
glycoprotein (S) is the most significant SARS-CoV neutralising and protective 
antigen. The binding of the Spike protein to its receptor Angiotensin Converting 
Enzyme 2 (ACE2) is responsible for SARS-CoV entry into cells. Vaccine 
strategies aiming at blocking/restricting infection by SARS-CoV mainly focus 
on targeting the Spike viral glycoprotein. Nonetheless, such strategy poses 
a singular dilemma for coronaviruses, as previous vaccination protocols have 
highlighted the possibility of immune-mediated enhancement of the disease.1,2
 Immune-mediated mechanisms, particularly antibody-dependent 
enhancement (ADE) have been exploited by a variety of viruses, including 
dengue virus, Feline Coronavirus (FCoV), and HIV, as alternative strategies to 
infect host cells.2,3 Besides interaction between viral protein and host receptor, 
these viruses can enter cells through binding of virus/immune-complexes to Fc-
receptor (FcR), complement-receptor or by inducing conformational change in 
envelope glycoproteins that are required for virus-cell membrane fusion.3 In the 
case of FcoV infection, immunisation of cats with recombinant vaccinia virus 
preparations expressing the FCoV Spike protein resulted in the induction of 
S-specific antibodies responsible for an enhanced susceptibility to infectious 
challenge.1 The enhanced infection of macrophages following antibody-mediated 
entry of feline coronavirus is responsible for the occurrence of deadly feline 
infectious peritonitis.
 We investigated whether a recombinant native full length Spike-protein 
trimer (triSpike) of SARS-CoV was able to elicit a neutralising and protective 
immune response. Furthermore, we explored the capacity of vaccine-induced 
anti-Spike immune-serum to mediate ADE of SARS-CoV infection. We adopted 
reasonable safety concerns regarding the use of SARS-CoV vaccine in humans, 
and explored new ways to investigate SARS pathogenesis.
Methods
This study was conducted from 17 July 2006 to 16 June 2008. 
Cell lines, expression vectors
VeroE6 (African green monkey kidney epithelial cells), K-562 (human 
chronic myelogenous leukaemia cells), U-937 (human histiocytic lymphoma 
cells), THP-1 (human acute monocytic leukaemia cells), SUP-T1 (human 
lymphoblastic leukaemia T lymphoblast), MOLT-3 (human acute lymphoblastic 
leukaemia T lymphoblast), MT4/R5 (Human T cell lymphoblast expressing 
CCR5), Raji (Burkitt’s lymphoma B lymphoblast), Daudi (Burkitt’s lymphoma 
B lymphoblast), ST486 (Burkitt’s lymphoma B lymphoblast lacking expression 
Jaume et al
32      Hong Kong Med J Vol 18 No 1 Supplement 2 February 2012
of FcγR), 721.221 (EBV-transfected human B cells), NK-
92 (malignant non-Hodgkin’s lymphoma NK cell), P388D1 
(murine macrophage-like lymphoblast), J774A.1 (murine 
monocyte/macrophage cells) were cultured in accordance 
with ATCC guidelines. Optimised DNA and Semliki Forest 
Virus expression vectors encoding SARS-CoV S-protein 
fused to a C-terminal FLAG-sequence have been described.4
Immunisation with inactivated SARS-CoV or 
recombinant Spike protein
For evaluation of ADE of triSpike-elicited serum, BALB/c 
mice 6 to 8 weeks old (n=4 per group) were immunised 
intraperitoneally with 2 μg of purified triSpike in presence 
or absence of 1 mg of aluminium hydroxide gel on days 0 
and 28. Animals in the control group received PBS with 1 
mg of aluminium hydroxide gel on the same days. Blood 
samples were collected by saphenous vein bleeding on days 
-1, 27 and 55 post-immunisation (in accordance with local 
guidelines), and sera were prepared and heat-inactivated.
 For comparison of SARS-CoV vaccines, BALB/c mice 
(n=4 per group) were immunised intraperitoneally with 
either 2 μg of recombinant codon-optimised SARS-CoV 
Spike full-length (Opt. Spike Flag; O.S.F; aa1-1255), 2 
μg of recombinant codon-optimised SARS-CoV Spike 
ectodomain (Opt. SpikeECD Flag; O.SECD.F; aa1-1184), 
2 μg of recombinant codon-optimised SARS-CoV Spike 
subunit 1 (Opt. S1 Flag; O.S1.F; aa1-757), or 10 μg of 
recombinant SARS-CoV Spike protein truncated early after 
the transmembrane domain (Soluble Spike Flag; Ssol.F; 
aa1-1193). An additional group immunised with 2 μg 
(Spike-equivalent) of γ-irradiated SARS-CoV virion was 
also included as well as a mock control group injected with 
saline solution (PBS). Two immunisations were performed 
in presence of 1 mg of aluminium hydroxide gel at 3-week 
intervals, and sera were collected on days -1, 27, and 55 
post-immunisation. Blood samples were harvested and 
handled as described above.
SARS-CoV pseudotype particles
Recombinant SARS-CoVpp lentiviral vectors expressing 
a luciferase reporter gene were produced from HEK293T 
cells as described elsewhere using 10 μg of plasmid 
pNL4.3.Luc R−E−pro− and 10 μg of plasmid pCDNA-S-
FLAG encoding codon-optimised SARS-CoV S protein.4 
For ADE assays, 25 μL of serial two-fold dilutions of heat-
inactivated mouse sera were incubated for 1 h at 37ºC with 
25 μL of pseudovirus (50 ng p24). 50μL of Raji cells, at 
2×106 cell/mL previously washed three times with serum-
free RPMI, were added to the antibody-SARS-CoVpp 
mixture in a 96-well plate. After adsorption for 1 h at 37°C, 
100 μL of RPMI 1640 containing 5% FCS were added. 
Medium was renewed 16 h later and cells were incubated 
for an additional 48 h, washed in PBS, lysed and luciferase 
activity measured for 10 sec in a MicroBeta Jet Counter 
(Perkin Elmer) according to the instructions provided by 
the supplier (Promega). For ADE blocking assays, Raji 
cells were pre-incubated for 15 min at 4ºC with 10 μg/mL of 
murine monoclonal antibody directed against human CD32 
(FcγRII, BD Pharmingen) or goat polyclonal antibody 
directed against human ACE2 (R&D Systems) prior to 
infection with SARS-CoVpp.
Lysosomotropic agent and protease inhibitors
Cells were pre-incubated with the indicated amounts of 
either ammonium chloride (NH
4
Cl) for 1 h, E-64d or 
Cathepsin L inhibitor (Cat L Inh) (Calbiochem) for 3 h 
prior to infection. Pseudoviruses (with or without serum) 
were mixed with the same concentrations of reagents in 
tubes and added to cells. After 5 h (E-64d or Cat L Inh) or 
7 h (NH
4
Cl), viruses were removed and replaced with fresh 
medium without drug. Cells were assayed for luciferase 
activity 60 to 65 h after infection.
Results
Production of a subunit SARS vaccine
We developed a SARS vaccine candidate (triSpike) based 
on recombinant native full-length Spike-protein trimers 
(the envelope glycoprotein involved in SARS-CoV entry 
into host cells). Our vaccine protocol elicited an in vivo 
neutralising and protective immune response in rodents.4 
In vitro Spike-specific serum blocked binding of the Spike 
protein to the ACE2 receptor and neutralised SARS-CoV 
infection of permissive cells.4
Investigation of immune-mediated enhancement of 
SARS-CoV infection
By using SARS-CoV Spike-pseudotyped viral particle 
(SARS-CoVpp),4 we analysed the capacity of triSpike-
elicited sera to trigger ADE2,3 of viral infection in vitro. The 
experiments exhibited opposite pattern according to cell 
types, while complement-inactivated sera from immunised 
animals still inhibit SARS-CoVpp entry in prototypic 
permissive cell lines, these sera induced virus penetration 
in human monocytic and lymphoblastic (B lineage) cell 
lines (Fig 1). Immune-mediated enhancement of infection 
was not restricted only to SARS-CoVpp, but also drove 
infection of human Raji B cells by live SARS-CoV (strain 
HK39849).
Unravelling molecular and biochemical pathways 
of antibody-dependent enhancement of SARS-CoV 
infection
To highlight differences, if any, in the ACE25 and FcR-
mediated entry pathways, we compared the effect of 
treatments by a lysosomotropic agent and protease 
inhibitors. Blockade of the acidification of the endosome, 
and annihilation of the cysteine protease activity did not 
abrogate ADE of SARS-CoVpp infection (Fig 2). In 
combination with the results of the investigation of the 
molecular pathway involved during the ADE process, entry 
into human haematopoietic cells occurred via an FcγR-
dependent4 and ACE2-, pH-, cysteine-protease-independent4 
pathways illustrating that ADE of virus infection is a novel 
cell entry mechanism of SARS-CoV (Fig 2).
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Fig 1. Susceptibility of haematopoietic cell lines to infection by SARS-CoV Spike pseudoparticles in presence of immune-serum
SARS-CoVpp were incubated in presence or absence of different dilutions (eg 1/1000, 1/2000, and 1/4000) of serum from PBS/Alum-
immunised (plain bars) or 2 μg triSpike/Alum-immunised (hatched bars) BALB/c mice for 1 h prior to addition to the indicated cells. Three 
days post infection, 1 volume of luciferase substrate reagent was added to wells and luminescence was measured (Figure amended with 
permission from the American Society for Microbiology from FIG. 1A of the original publication6)
Fig 2. Antibody-mediated entry of SARS-CoVpp is independent of acidic pH and cysteine-protease activity of the endosomal/
lysosomal compartment
Comparison of pH and protease requirements for ACE2- versus antibody-mediated entry of SARS-CoVpp. Prior to infection, VeroE6 
and Raji cells were preincubated with indicated concentration of (a) ammonium chloride (NH4Cl) for 1 h or (b) broad cysteine proteases 
inhibitor (E-64d) or (c) Cathepsin L inhibitor (Cat L Inh) for 3 h. SARS-CoVpp ± 1/2000 anti-Spike serum (containing the indicated 
concentration of chemicals) was then added to the cells. (d) Cell surface expression of hCD32 protein on Raji cells following NH4Cl 
treatment. Raji cells were incubated with indicated concentrations of NH4Cl for 1, 3, and 5 h (not shown). Cells were then labelled with 
anti-hCD32 antibody and subjected to flow cytometry (Figure amended with permission from the American Society for Microbiology from 
FIG. 7 of the original publication6)
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Fig 3. Effect of different vaccine formulation on SARS-CoV antibody-mediated enhancement of viral entry
Schematic illustration of different forms of recombinant SARS-CoV Spike used for vaccination of BALB/c mice. (a) Positions of the 
different regions are indicated according to Swissprot accession no. P59594. Neutralising versus enhancing abilities of mouse sera 
raised after immunisation with different SARS vaccine candidates are shown. SARS-CoVpp were incubated in presence or absence 
of serial dilutions of pooled serum from four vaccinated BALB/c mice as indicated for 1 h prior to addition to the (b) VeroE6 or (c) Raji 
cells. Three days post-infection luminescence was measured. (d) The binding activity toward recombinant SARS-CoV Spike protein in 
1/2000 dilution of pooled serum from vaccinated mice was estimated by enzyme-linked immune-absorbent assay (Figure amended with 
permission from the American Society for Microbiology from FIG. 8 of the original publication6)
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SARS vaccine candidates and antibody-dependent 
enhancement of SARS-CoV infection
By comparing neutralising versus enhancing potency of 
different SARS vaccine candidates (subunit vaccines and 
whole inactivated virion), distinct patterns of ADE were 
highlighted, despite highly similar abilities of the immune-
sera to neutralise infection of ACE2-expressing cells (Fig 3). 
Noticeably, two out of the five tested immunogens (Spike 
ectodomain only and whole inactivated virion) displayed 
relatively high neutralising titres without triggering SARS-
CoVpp entry into immune cells. Preliminary results showed 
differences in the nature of humoral responses elicited by 
the five immunogens, as indicated by presence or absence 
of IgG2a in non-enhancing and enhancing sera, respectively 
(Fig 3).
Discussion
Currently, there is no licensed vaccine against a human 
coronavirus. Nonetheless, vaccines against some animal 
coronaviruses have been generated. Other vaccines are 
difficult to produce owing to immune enhancement of 
infection.1,2
 Our quest to produce an efficient vaccine against 
SARS-CoV has shed light on the incidence of opposite 
outcomes (ie neutralising and enhancing) depending 
on the patterns of expression of Fc receptor by the 
host cells. Notably, occurrence of antibody-mediated 
infection seems fairly complex as the expression of a 
particular class of FcR is not sufficient to indubitably 
predict the occurrence of ADE. Indeed, only background 
levels of SARS-CoVpp transduction were observed 
with several immune cells (human K-562, MT4-R5, 
721.221, and murine P388D1, J774A.1 cell lines) despite 
their expression of the same FcγR (FcγRII) as THP-
1, Raji, and Daudi cells (Fig 1). The reasons for this 
phenomenon remain unclear, but the involvement of FcR 
subfamilies, such as activating and inhibiting isoforms 
(ITAM- and ITIM-bearing FcR, respectively) and/or allelic 
variants, ie FcRγIIA-H131 and FcRγIIA-R131, is highly 
speculative.
 Our studies on the biochemical requirements along 
the antibody-mediated infection have proved this pathway 
singularly distinct from the natural (ie ACE2) entry 
mechanism. In fact, ADE of SARS-CoVpp entry into 
human haematopoietic cells occurred via an ACE2-, pH- 
and cysteine-protease-independent route, illustrating that 
antibody-mediated infection is a novel cell entry mechanism 
of SARS-CoV.
 Investigation of the neutralising versus enhancing 
potency of immune-sera elicited by different SARS vaccine 
candidates have highlighted distinct patterns of ADE, 
despite highly similar abilities to neutralise SARS-CoV 
infection. Further studies of the mechanisms underlying 
ADE of SARS-CoV infection are needed, particularly 
to unravel which viral epitope(s) or immunoglobulin 
isotype(s) are responsible for the enhanced infection.
 Because of antibody-mediated infection of SARS-
CoV, we hypothesised that the ADE phenomenon might 
participate in SARS pathogenesis. Indeed, infection by 
SARS-CoV is not confined to the lungs, but also involves 
other organs, most importantly cells of the immune system. 
Direct infection of haematopoietic cells by SARS-CoV may 
provide a partial explanation for the widespread destruction 
of the lymphoid tissue and the cytokinic deregulation 
in many SARS patients. Nonetheless, it is not clear how 
SARS-CoV gets a foothold into the immune cells as they 
do not express the putative SARS-CoV receptor ACE-2. 
Antibody-dependent enhancement of SARS-CoV infection, 
in addition to other alternative entry pathways (involving 
C-type lectin), may provide SARS-CoV versatility in entry 
routes allowing it to broaden its target options.
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